Notice of Early Expiration of PAR-19-078, Molecular and Genetic Characterization of Inborn Errors of Immunity (R01 Clinical Trial Not Allowed)"
Notice NOT-AI-22-005 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 29, 2021 Category: Research Source Type: funding
Notice of Change to Review Dates of PAR-22-054, Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed)
Notice NOT-RM-22-003 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 10, 2021 Category: Research Source Type: funding
Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01 - Clinical Trial Optional)
Funding Opportunity PAR-21-353 from the NIH Guide for Grants and Contracts. This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future. Having an accurate screening test, as well as demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a "high priority" conditi...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 9, 2021 Category: Research Source Type: funding
Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R03 - Clinical Trial Optional)
Funding Opportunity PAR-21-354 from the NIH Guide for Grants and Contracts. This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future. Having an accurate screening test, as well as demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a "high priority" conditi...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 9, 2021 Category: Research Source Type: funding
Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)
Funding Opportunity PAR-21-355 from the NIH Guide for Grants and Contracts. This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future. Having an accurate screening test, as well as demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a "high priority" conditi...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 9, 2021 Category: Research Source Type: funding
Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed)
Funding Opportunity PAR-22-054 from the NIH Guide for Grants and Contracts. As part of the Gabriella Miller Kids First Pediatric Research Program (Kids First), the NIH invites applications to submit samples from pediatric cohorts for whole genome sequencing at a Kids First-supported sequencing center. Applicants are encouraged to propose sequencing of existing pediatric cancer cohorts to elucidate the genetic contribution (somatic and/or germline) to childhood cancers, or to expand the range of disorders included within the Kids First Data Resource to investigate the genetic etiology of structural birth defects. The pro...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 1, 2021 Category: Research Source Type: funding
NIMH Priorities on Research Using Genetically Modified Nonhuman Primates.
Notice NOT-MH-22-010 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 13, 2021 Category: Research Source Type: funding
Limited Competition: Renewal of the Caenorhabditis Intervention Testing Program (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-AG-22-029 from the NIH Guide for Grants and Contracts. The purpose of the Caenorhabditis Interventions Testing Program (CITP) is to test, under standardized conditions at a consortium of three sites, potential intervention strategies that may moderate/alleviate health declines associated with aging across genetically diverse species and strains of Caenorhabditis. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 23, 2021 Category: Research Source Type: funding
Notice of Change to Research Strategy Section Page Limits for RFA-DK-21-502, Limited Competition for the Data Coordinating Center (DCC) for the NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) (U24 Clinical Trial Optional)
Notice NOT-DK-21-028 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 22, 2021 Category: Research Source Type: funding
Limited Competition:Caenorhabditis Intervention Testing Program Data Coordinating Center (U24 Clinical Trial Not Allowed)
Funding Opportunity RFA-AG-22-028 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to maintain the Data Coordinating Center (DCC) for the Caenorhabditis Intervention Testing Program (CITP,) to coordinate data collection and analysis among the laboratories participating in the CITP, and to provide public access to standard operating procedures and experimental outcomes (including an accessible, annotated, and user-friendly database). The purpose of the CITP is to test, under standardized conditions at a consortium of three sites, potential intervention strategies ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 21, 2021 Category: Research Source Type: funding
Pancreatic Cancer Detection Consortium: Management and Data Coordination Unit (U24 Clinical Trial Not Allowed)
Funding Opportunity PAR-21-335 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the Research Units (RUs), one of the two scientific components of the Pancreatic Cancer Detection Consortium (PCDC), to conduct research on early detection of pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursor lesions to identify those patients who are at high risk of progression to cancer. The PCDC will continue to address one of the four research priorities identified in the National Cancer Institute's 2014 Scientific Framework ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 16, 2021 Category: Research Source Type: funding
Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)
Funding Opportunity PAR-21-334 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the Research Units (RUs), one of the two scientific components of the Pancreatic Cancer Detection Consortium (PCDC), to conduct research on early detection of pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursor lesions to identify those patients who are at high risk of progression to cancer. The PCDC will continue to address one of the four research priorities identified in the National Cancer Institute's 2014 Scientific Framework ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 16, 2021 Category: Research Source Type: funding
Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)
Funding Opportunity PAR-21-330 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from the control arm participants. Avai...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 8, 2021 Category: Research Source Type: funding
Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)
Funding Opportunity PAR-21-322 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 2, 2021 Category: Research Source Type: funding
Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)
Funding Opportunity PAR-21-323 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants will support innovative studies designed to investigate biological/genetic bases of cancer health disparities, such as (1) mechanistic studies of biological factors associated with cancer health disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the d...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 2, 2021 Category: Research Source Type: funding
